Raymond J. Andersen
Corporate Officer/Principal bei University of British Columbia
Aktive Positionen von Raymond J. Andersen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| University of British Columbia | Corporate Officer/Principal | 01.01.1977 | - |
Karriereverlauf von Raymond J. Andersen
Ehemalige bekannte Positionen von Raymond J. Andersen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ESSA PHARMA INC. | Direktor/Vorstandsmitglied | 11.10.2010 | 31.07.2019 |
| Technik-/Wissenschafts-/F&E-Leiter | 11.10.2010 | 31.07.2019 | |
| Gründer | 06.01.2009 | 31.07.2019 | |
| Unternehmenssekretär | 06.01.2009 | 31.07.2019 | |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Gründer | 26.12.2003 | - |
Ausbildung von Raymond J. Andersen
| University of Alberta | Undergraduate Degree |
| University of California, Berkeley | Graduate Degree |
| University of California San Diego | Doctorate Degree |
Statistik
International
| Kanada | 5 |
| Vereinigte Staaten | 3 |
Operativ
| Founder | 2 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Consumer Services | 5 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ESSA PHARMA INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
- Börse
- Insiders
- Raymond J. Andersen
- Erfahrung
